These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 5781083)

  • 21. Relationships between calcium and oxalic acid intake in the diet and their excretion in the urine of normal and renal-stone-forming subjects.
    Marshall RW; Cochran M; Hodgkinson A
    Clin Sci; 1972 Jul; 43(1):91-9. PubMed ID: 5040764
    [No Abstract]   [Full Text] [Related]  

  • 22. [Results of medical treatment of renal lithiasis 5 years later].
    Ruiz Marcellán FJ; Bernshtam J; Pinto B
    Actas Urol Esp; 1982; 6(5):273-6. PubMed ID: 7158456
    [No Abstract]   [Full Text] [Related]  

  • 23. The effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on calcium oxalate crystalluria in recurrent renal stoneformers.
    Robertson WG; Peacock M; Marshall RW; Knowles F
    Clin Sci Mol Med; 1974 Jul; 47(1):13-22. PubMed ID: 4277691
    [No Abstract]   [Full Text] [Related]  

  • 24. The urinary excretion of oxalic acid and magnesium in oxalate urolithiasis.
    Takasaki E; Shimano E
    Invest Urol; 1967 Nov; 5(3):303-12. PubMed ID: 6073639
    [No Abstract]   [Full Text] [Related]  

  • 25. The relation between the concentration of calcium salts in the urine and renal stone composition in patients with calcium-containing renal stones.
    Marshall RW; Cochran M; Robertson WG; Hodgkinson A; Nordin BE
    Clin Sci; 1972 Sep; 43(3):433-41. PubMed ID: 5077518
    [No Abstract]   [Full Text] [Related]  

  • 26. [Dietary management of renal stone disease--with special reference to oxalate].
    Iguchi M; Tsujihashi H; Nagai N; Kataoka K; Kato Y; Kohri K; Kurita T; Yachiku S
    Nihon Hinyokika Gakkai Zasshi; 1985 Mar; 76(3):293-302. PubMed ID: 4032896
    [No Abstract]   [Full Text] [Related]  

  • 27. [Crystallization inhibitory substances in urine and kidney calculi].
    Baumann JM; Ganz U; Felix R; Fleisch H; Rutishauser G
    Helv Chir Acta; 1974 Sep; 41(4):417-20. PubMed ID: 4369523
    [No Abstract]   [Full Text] [Related]  

  • 28. [Experimental investigation on the possibility of influencing the solubility of mineral renal stones].
    Knappwost A; Matouschek E
    Urol Int; 1973; 28(1):9-20. PubMed ID: 4693759
    [No Abstract]   [Full Text] [Related]  

  • 29. Calcium and other electrolytes in renal lithiasis.
    Phillips MJ
    Lancet; 1969 Feb; 1(7590):368. PubMed ID: 4179370
    [No Abstract]   [Full Text] [Related]  

  • 30. Rational therapy of nephrolithiasis, Part I.
    Pak CY
    Ration Drug Ther; 1984 Nov; 18(11):1-6. PubMed ID: 6536977
    [No Abstract]   [Full Text] [Related]  

  • 31. [Idiopathic calcium oxalate urinary lithiasis: new physiopathological approaches].
    Berland Y
    Nephrologie; 1999; 20(7):363-9. PubMed ID: 10642984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of verapamil on urinary calcium and oxalate excretion in renal stone formers].
    Iguchi M; Ikegami M; Kiwamoto H; Umekawa T; Ishikawa Y; Kohri K; Kurita T
    Hinyokika Kiyo; 1993 May; 39(5):425-31. PubMed ID: 8322624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The development of kidney stones].
    Schmucki O
    ZFA (Stuttgart); 1981 Jan; 57(1):7-12. PubMed ID: 7222961
    [No Abstract]   [Full Text] [Related]  

  • 34. Studies on bladder stone disease in Egyptian children. VI. Crystalluria in the stone patients.
    Loutfi A; Van Reen R; Abdel-Hamid G
    J Egypt Med Assoc; 1974; 57(3-4):137-45. PubMed ID: 4430772
    [No Abstract]   [Full Text] [Related]  

  • 35. [The significance of oxaluria reduction in pyridoxine prevention of Ca-oxalate nephrolithiasis (author's transl)].
    Revúsová V; Gratzlová J; Zvara V; Krídl J; Suchánek B
    Cas Lek Cesk; 1982 Feb; 121(6):163-6. PubMed ID: 7060073
    [No Abstract]   [Full Text] [Related]  

  • 36. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery.
    Asplin JR; Coe FL
    J Urol; 2007 Feb; 177(2):565-9. PubMed ID: 17222634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxalic acid and the hyperoxaluric syndromes.
    Williams HE
    Kidney Int; 1978 May; 13(5):410-7. PubMed ID: 351269
    [No Abstract]   [Full Text] [Related]  

  • 38. Reduction of urine oxalate during long-term thiazide therapy in patients with calcium urolithiasis.
    Cohanim M; Yendt ER
    Invest Urol; 1980 Sep; 18(2):170-3. PubMed ID: 7410033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hyperoxaluria in renal calculosis and in Crohn's disease].
    Marangella M; Maddalena D; Fruttero B; Bruno M; Malfi B; Linari F
    Minerva Nefrol; 1979; 26(4):543-8. PubMed ID: 542224
    [No Abstract]   [Full Text] [Related]  

  • 40. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions.
    Pak CY; Heller HJ; Pearle MS; Odvina CV; Poindexter JR; Peterson RD
    J Urol; 2003 Feb; 169(2):465-9. PubMed ID: 12544288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.